Healthcare Reimbursement News

Facing MACRA Without Fear

David Lareau offers insights into the future of the Medicare and CHIP Reauthorization Act of 2015.

By David Lareau July 7, 2017

Physician Partnerships in the Era of ACA Repeal and Replace

Bundled care for the uninsured may presents an effective solution to the looming challenges facing the healthcare industry.

By Jeff Helton,  PHD, FHFMA, CMA, CFE July 5, 2017

How Finance Can Play a Pivotal Role in the Transition to MACRA

As a central entity in a healthcare practice, the finance department is in a unique position to review processes and implement improvements as the MACRA transition begins.

By Karen England July 5, 2017

Overview of the Better Care Reconciliation Act as Drafted on June 28, 2017

This presentation summarizes the Better Care Reconciliation Act as drafted on June 28, 2017.

By HFMA June 30, 2017

Video: Key Points of Focus for Hospitals: CMS Strategy, Bundled Payment, and Cost of Care

Larry Goldberg, principal, Larry Goldberg Consulting, takes a look at bundled payments, quality outcomes, and the cost of providing services.

By HFMA June 30, 2017

Managing Care Variation: Optimizing Total Joint Replacement Bundle

Advisory Board’s Sean Angert discusses ways healthcare organizations can improve performance in bundled payment programs.

By Sean Angert June 29, 2017

No-Pay Policy for Non-Emergent ED Use Spreading

A growing number of health plans are not paying for non-emergency patient use of the ED.

By Rich Daly June 29, 2017

Bad Debt, Charity Care Contribute To Differences in Patient Revenue

Low margin hospitals may be receiving reduced payments from commercial insurance, which may contribute to their lower net patient revenues.

By HFMA June 29, 2017

10 Critical Medicaid Trends to Watch

It is important for hospitals and health systems to forecast the impact of proposed healthcare legislation on Medicaid payments, eligibility teams, and patients.

By Marie Hinds June 29, 2017

Part B Drugs Revisited—Yet Again

Payment and pricing for Medicare Part B drugs are subjects of much discussion again following the decision by CMS to withdraw its planned pilot projects for these drugs.

By Gail R Wilensky, PhD June 20, 2017
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-leaderboard' ); } );

{{ loadingHeading }}

{{ loadingSubHeading }}

We’re having trouble logging you in.

For assistance, contact our Member Services Team.

Your session has expired.

Please reload the page and try again.